Your browser is no longer supported. Please, upgrade your browser.
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.88 Insider Own1.60% Shs Outstand47.70M Perf Week0.16%
Market Cap35.40M Forward P/E- EPS next Y-2.03 Insider Trans-1.25% Shs Float47.27M Perf Month-28.12%
Income-231.80M PEG- EPS next Q-0.48 Inst Own- Short Float30.03% Perf Quarter-48.08%
Sales176.40M P/S0.20 EPS this Y9.30% Inst Trans-13.80% Short Ratio8.88 Perf Half Y-57.28%
Book/sh6.43 P/B0.12 EPS next Y-20.50% ROA-25.50% Target Price- Perf Year-92.03%
Cash/sh1.75 P/C0.43 EPS next 5Y29.00% ROE-64.20% 52W Range0.70 - 9.80 Perf YTD-63.35%
Dividend- P/FCF- EPS past 5Y16.45% ROI-48.20% 52W High-92.37% Beta1.60
Dividend %- Quick Ratio2.00 Sales past 5Y-13.70% Gross Margin83.10% 52W Low6.78% ATR0.08
Employees344 Current Ratio2.40 Sales Q/Q-36.30% Oper. Margin- RSI (14)40.07 Volatility6.20% 8.87%
OptionableYes Debt/Eq0.72 EPS Q/Q86.50% Profit Margin- Rel Volume1.05 Prev Close0.77
ShortableYes LT Debt/Eq0.72 EarningsMay 05 AMC Payout- Avg Volume1.60M Price0.75
Recom3.10 SMA20-7.84% SMA50-18.88% SMA200-60.90% Volume1,670,804 Change-2.76%
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Nov-09-17Initiated Oppenheimer Perform
Nov-08-17Initiated H.C. Wainwright Buy $35
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
May-06-20 07:23PM  DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600 PR Newswire -8.50%
01:27PM  Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y Zacks
May-05-20 06:15PM  Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:00PM  Acorda Reports First Quarter 2020 Financial Results and Provides Business Update Business Wire
Apr-28-20 07:00AM  Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020 Business Wire
Apr-24-20 11:49AM  Acorda (ACOR) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-16-20 05:45PM  Acorda Therapeutics (ACOR) Flat As Market Gains: What You Should Know Zacks
Apr-07-20 05:50PM  Acorda Therapeutics (ACOR) Stock Moves -0.11%: What You Should Know Zacks
12:37PM  Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study Zacks
11:14AM  Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue Zacks
Apr-03-20 08:31AM  Immunomedics (IMMU) in Focus: Stock Moves 5% Higher Zacks
Apr-02-20 10:08AM  Nabriva (NBRV) Looks Good: Stock Adds 5.7% in Session Zacks +6.24%
Mar-30-20 08:06AM  New Strong Buy Stocks for March 30th Zacks -5.37%
Mar-17-20 12:00PM  What Makes Acorda (ACOR) a New Buy Stock Zacks
Mar-14-20 11:30AM  Why Is Acorda (ACOR) Down 54.7% Since Last Earnings Report? Zacks
Feb-24-20 07:00AM  Acorda Therapeutics to Present at Cowen Annual Health Care Conference Business Wire -9.21%
Feb-18-20 01:44AM  Edited Transcript of ACOR earnings conference call or presentation 13-Feb-20 1:30pm GMT Thomson Reuters StreetEvents -9.50%
Feb-14-20 11:57AM  Acorda (ACOR) Q4 Earnings Top Estimates, Revenues Fall Y/Y Zacks -6.77%
Feb-13-20 10:25AM  Acorda Therapeutics (ACOR) Reports Q4 Loss, Tops Revenue Estimates Zacks
09:15AM  Acorda (ACOR) Beats Earnings & Revenues Estimates in Q4 Zacks
07:00AM  Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results Business Wire
Feb-10-20 10:20AM  What's in Store for Acorda (ACOR) This Earnings Season? Zacks
Feb-06-20 12:31PM  Earnings Preview: Acorda Therapeutics (ACOR) Q4 Earnings Expected to Decline Zacks
05:51AM  Acorda Therapeutics, Inc. (NASDAQ:ACOR): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Jan-30-20 07:00AM  Acorda Fourth Quarter/Year End 2019 Update: Webcast/Conference Call Scheduled for February 13, 2020 Business Wire
Jan-24-20 08:54AM  Implied Volatility Surging for Acorda (ACOR) Stock Options Zacks -11.39%
Jan-15-20 07:00AM  Acorda Provides 2019 Highlights and 2020 Guidance at J.P. Morgan Healthcare Conference Business Wire -8.97%
Jan-08-20 07:00AM  Acorda to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire -7.38%
Jan-07-20 10:55AM  Acorda Therapeutics (ACOR) in Focus: Stock Moves 5.7% Higher Zacks
Jan-03-20 07:55AM  The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger Benzinga +15.82%
Dec-26-19 07:00AM  Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes due June 2021; New Convertible Secured Notes Mature December 2024 Business Wire +43.23%
Dec-23-19 05:30AM  Acorda Therapeutics Announces Private Exchange of $276 Million of Its 1.75% Convertible Senior Notes Due 2021 Business Wire
Dec-12-19 10:31AM  Hedge Funds Are Getting Burned By Acorda Therapeutics Inc (ACOR) Insider Monkey
Dec-04-19 11:30AM  Acorda (ACOR) Down 13.5% Since Last Earnings Report: Can It Rebound? Zacks -11.17%
Dec-02-19 10:22AM  Acorda (ACOR) Down More Than 80% Year to Date: Here's Why Zacks
Nov-27-19 07:00AM  Acorda Therapeutics Elects John Kelley Chair, Board of Directors TEST Business Wire Releases
07:00AM  Acorda Therapeutics Elects John Kelley Chair, Board of Directors Business Wire
Nov-12-19 07:00AM  Acorda Therapeutics Announces Departure of President, International & General Counsel Business Wire -9.59%
Nov-08-19 10:21AM  Is Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-07-19 11:08AM  Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales Zacks
11:05AM  Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates Zacks
11:04AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
08:50AM  Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1% Zacks
Nov-06-19 04:40PM  Were Hedge Funds Right About Dumping Acorda Therapeutics Inc (ACOR)? Insider Monkey
04:28PM  Edited Transcript of ACOR earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
10:56AM  Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View Zacks
10:34AM  Intercept (ICPT) Earnings and Sales Miss Estimates in Q3 Zacks
Nov-05-19 11:45AM  Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates Zacks +19.00%
11:09AM  Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Nov-04-19 05:25PM  Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:00PM  Acorda Provides Update for Third Quarter Ended September 30, 2019 Business Wire
11:18AM  AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates Zacks
Nov-01-19 02:49PM  Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks +21.21%
12:07PM  Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
Oct-31-19 12:40PM  Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3 Zacks -9.84%
12:33PM  Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates Zacks
11:54AM  Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss Zacks
09:26AM  Insmed (INSM) in Focus: Stock Moves 7.1% Higher Zacks
Oct-28-19 10:32AM  Acorda Therapeutics (ACOR) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-25-19 07:12AM  The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug Benzinga
Oct-24-19 11:24AM  Acorda (ACOR) to Post Q3 Earnings: What's in the Cards? Zacks -26.06%
07:36AM  The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise Benzinga
Oct-23-19 04:00PM  Acorda Therapeutics Implements Corporate Restructuring, Provides Third Quarter 2019 Update Business Wire +11.78%
Oct-22-19 07:00AM  Acorda Launches New Tool for People with Parkinsons to Improve Communication About OFF Periods Business Wire
Oct-21-19 07:00AM  Acorda Third Quarter 2019 Update: Webcast/Conference Call Scheduled for November 4, 2019 Business Wire
Oct-07-19 10:00AM  UPDATE 1-U.S. Supreme Court rejects Acorda appeal in MS drug patent fight Reuters
Oct-03-19 09:00AM  Acorda (ACOR) Upgraded to Buy: Here's What You Should Know Zacks
Sep-26-19 08:40AM  Medicines Company (MDCO) Jumps: Stock Rises 5.5% Zacks
Sep-25-19 06:22PM  Protalix Completes Enrollment in Third Fabry Disease Study Zacks
06:18PM  Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study Zacks
07:00AM  Acorda Therapeutics to Present at the 2019 Cantor Healthcare Conference Business Wire
Sep-18-19 10:33AM  Acceleron Discontinues Mid-Stage Muscular Dystrophy Study Zacks
08:42AM  Lexicon (LXRX) Catches Eye: Stock Jumps 7.3% Zacks
07:00AM  Acorda to Present Data at the International Congress of Parkinsons Disease and Movement Disorders Business Wire
Sep-16-19 10:29AM  Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease Zacks -7.51%
Sep-13-19 10:30AM  Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks
08:42AM  Ligand (LGND) Surges: Stock Moves 6.3% Higher Zacks
Sep-12-19 08:35AM  Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session Zacks
Sep-11-19 11:37AM  Ultragenyx to Submit sBLA for Label Expansion of Crysvita Zacks
Sep-10-19 09:01AM  Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks +26.98%
07:59AM  Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review Zacks
Sep-09-19 03:51PM  Did Changing Sentiment Drive Acorda Therapeutics's (NASDAQ:ACOR) Share Price Down A Painful 91%? Simply Wall St. +12.50%
Sep-03-19 11:00AM  Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why Zacks -8.98%
Aug-31-19 09:32AM  Why Is Acorda (ACOR) Down 46.8% Since Last Earnings Report? Zacks
Aug-23-19 09:15AM  Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 7.5% Zacks
07:38AM  Retrophin Down on Neurological Disorder Drug Study Failure Zacks
Aug-21-19 06:03PM  Synlogic Discontinues Development of SYNB1020, Stock Down Zacks
08:42AM  Moderna (MRNA) Jumps: Stock Rises 5.6% Zacks
Aug-20-19 08:34AM  Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment Zacks +9.90%
07:44AM  Acorda Therapeutics Enters Oversold Territory Zacks
Aug-14-19 09:10AM  Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD Zacks -12.45%
Aug-13-19 09:50AM  Regeneron Ebola Treatment Shows Promise, Study Stopped Early Zacks
Aug-12-19 08:37AM  Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates Zacks
Aug-09-19 11:09AM  Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat Zacks
Aug-08-19 10:45AM  Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 Zacks
10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
09:26AM  Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates Zacks
Aug-07-19 05:40PM  Edited Transcript of ACOR earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-19 11:54AM  Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark Zacks -48.93%
10:53AM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wasman JanePresident, Intl and GCDec 02Sale1.602,2273,553117,420Dec 04 07:53 AM
Sabella Lauren MChief Commercial OfficerDec 02Sale1.601,5132,42112,624Dec 04 07:51 AM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 02Sale1.601,1761,88012,961Dec 04 07:49 AM
COHEN RONPresident and CEODec 02Sale1.604,6997,505607,287Dec 04 07:47 AM